Literature DB >> 31399530

Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.

Jennifer L J Heaney1, Alex Richter1, Stella Bowcock2, Guy Pratt3, J Anthony Child4, Graham Jackson5, Gareth Morgan6, Ingemar Turesson7, Mark T Drayson8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31399530      PMCID： PMC7109726          DOI： 10.3324/haematol.2019.224360

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Martha Q Lacy; Robert A Kyle
Journal:  Blood Rev       Date:  2007-03-26       Impact factor: 8.250

2.  Serum free light chains in patients with HIV infection: their association with markers of disease severity and antiretroviral use.

Authors:  Annalise E Zemlin; Hayley Ipp; Megan A Rensburg; Jurie J Germishuys; Monika M Esser; Madeleen Olivier; Rajiv T Erasmus
Journal:  J Clin Pathol       Date:  2014-12-01       Impact factor: 3.411

3.  Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.

Authors:  John P Campbell; Jennifer L J Heaney; Meena Shemar; Dene Baldwin; Ann E Griffin; Emma Oldridge; Margaret Goodall; Zaheer Afzal; Tim Plant; Mark Cobbold; Roy Jefferis; Joannes F M Jacobs; Christopher Hand; Mark T Drayson
Journal:  Clin Chem Lab Med       Date:  2017-03-01       Impact factor: 3.694

4.  Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.

Authors:  Ingemar Turesson; Stephanie A Kovalchik; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Lynn R Goldin; Mark T Drayson; Ola Landgren
Journal:  Blood       Date:  2013-11-12       Impact factor: 22.113

Review 5.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

6.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

7.  Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case-control study using electronic records.

Authors:  Elizabeth A Shephard; Richard D Neal; Peter Rose; Fiona M Walter; Emma J Litt; William T Hamilton
Journal:  Br J Gen Pract       Date:  2015-02       Impact factor: 5.386

8.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Kim Cocks; Sue E Bell; Alex J Szubert; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; J Anthony Child
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

9.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Graham H Jackson; Faith E Davies; Charlotte Pawlyn; David A Cairns; Alina Striha; Corinne Collett; Anna Hockaday; John R Jones; Bhuvan Kishore; Mamta Garg; Cathy D Williams; Kamaraj Karunanithi; Jindriska Lindsay; Matthew W Jenner; Gordon Cook; Nigel H Russell; Martin F Kaiser; Mark T Drayson; Roger G Owen; Walter M Gregory; Gareth J Morgan
Journal:  Lancet Oncol       Date:  2018-12-14       Impact factor: 41.316

10.  Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database.

Authors:  R D Neal; N U Din; W Hamilton; O C Ukoumunne; B Carter; S Stapley; G Rubin
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640
View more
  3 in total

1.  A Cohort Study of Free Light Chain Ratio in Combination with Serum Protein Electrophoresis as a First-Line Test in General Practice.

Authors:  Birgitte Sandfeld-Paulsen; Ninna Aggerholm-Pedersen; Mie Hessellund Samson; Holger Jon Møller
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

2.  Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.

Authors:  Danilo De Novellis; Raffaele Fontana; Angela Carobene; Bianca Serio; Idalucia Ferrara; Maria Carmen Martorelli; Laura Mettivier; Roberto Guariglia; Serena Luponio; Immacolata Ruggiero; Matteo D'Addona; Tiziana Di Leo; Valentina Giudice; Carmine Selleri
Journal:  Biomedicines       Date:  2022-07-10

3.  Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity.

Authors:  Jennifer L J Heaney; Sian Faustini; Lili Evans; Alec Rapson; Emily Collman; Annabelle Emery; John P Campbell; Sally Moore; Margaret Goodall; Zaheer Afzal; Iain L Chapple; Guy Pratt; Mark T Drayson
Journal:  Eur J Haematol       Date:  2022-02-28       Impact factor: 3.674
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.